Dianthus Therapeutics, Inc./$DNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Ticker
$DNTH
Sector
Primary listing
Employees
92
Headquarters
Website
DNTH Metrics
BasicAdvanced
$4.2B
-
-$4.20
1.24
-
Price and volume
Market cap
$4.2B
Beta
1.24
52-week high
$88.02
52-week low
$13.37
Average daily volume
1.1M
Financial strength
Current ratio
13.323
Quick ratio
13.157
Long term debt to equity
0.207
Total debt to equity
0.281
Profitability
EBITDA (TTM)
-177.822
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-7,973.33%
Operating margin (TTM)
-8,739.34%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-24.58%
Return on equity (TTM)
-38.38%
Valuation
Price to revenue (TTM)
1,517.393
Price to book
7.01
Price to tangible book (TTM)
7.01
Price to free cash flow (TTM)
-23.898
Free cash flow yield (TTM)
-4.18%
Free cash flow per share (TTM)
-3.348
Growth
Revenue change (TTM)
-67.35%
Earnings per share change (TTM)
64.82%
3-year revenue growth (CAGR)
-31.80%
3-year earnings per share growth (CAGR)
-49.46%
DNTH News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dianthus Therapeutics, Inc. stock?
Dianthus Therapeutics, Inc. (DNTH) has a market cap of $4.2B as of March 20, 2026.
What is the P/E ratio for Dianthus Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Dianthus Therapeutics, Inc. (DNTH) stock is 0 as of March 20, 2026.
Does Dianthus Therapeutics, Inc. stock pay dividends?
No, Dianthus Therapeutics, Inc. (DNTH) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next Dianthus Therapeutics, Inc. dividend payment date?
Dianthus Therapeutics, Inc. (DNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Dianthus Therapeutics, Inc.?
Dianthus Therapeutics, Inc. (DNTH) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.